American Shared Hospital Services (AMS) Earnings Call Transcript & Summary

May 14, 2024

NYSE American US Health Care Health Care Providers and Services earnings 29 min

Earnings Call Speaker Segments

Kirin Smith

executive
#1

Thanks, operator, and I'm glad each of you could be with us. After the market closed this afternoon, AMS put out its earnings press release for the first quarter of 2024. Should you want a copy, you can find one on the company's site, www.ashs.com, by clicking the Investors tab and then choosing press releases. Ahead of passing the call to management, I'd like to offer a few comments regarding forward-looking statements. Kindly be aware that a number of remarks shared on this conference call about the company's future expectations, plans and prospects count as forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Quite a few important factors—including the items addressed in the company's SEC filings—might lead actual results to differ materially from the picture those forward-looking statements paint. Those filings include the quarterly report on Form 10-K for the year ended December 31, 2022, and the definitive proxy statement for the Annual Meeting of Shareholders that was held on June 20, 2023. The company assumes no obligation to update any information contained in this conference call. Before I turn things over to Ray, let me walk everyone through our Q&A policy: each participant receives time for one question plus one follow-up. And as is our habit, we're happy to take any additional questions off-line at whatever point suits you. With that, I'll pass things to Ray Stachowiak, our Executive Chairman and CEO. Ray, the floor is yours.

Ray Stachowiak

executive
#2

Thanks, Kirin. Hello, everyone, and good afternoon. We appreciate you being with us for the conference call covering our earnings for the first quarter of 2024. I'll start things off with a few comments, and after that I'll hand things over to Bob Hiatt, who serves as our CFO, so he can walk through the financial details from Q1. Once our prepared comments are finished, we'll take your questions. But before getting into the numbers, I want to recognize that our Chief Executive Officer, Peter Gaccione, passed away unexpectedly. This loss has hit us hard, and Peter will be missed enormously. Over the past 18 months, his passion, his integrity, and the empowering way he led left a mark on this organization, and the enormous things he did for AMS are something we will always remember. His legacy continues, and to his family, his friends, and his colleagues, we send our wishes for very happy memories. Because of Peter's passing, we made several management announcements aimed at keeping operations running smoothly while we take advantage of the growth path we're on. Along with my Executive Chairman duties, I have stepped into the CEO position, and Craig Tagawa, who was the company's President, is now both President and Chief Operating Officer. Bob Hiatt remains in place as our Chief Financial Officer. Ernie Bates stays on as Vice President of International Sales and Marketing, and Curtis Ellis remains American Shield Hospital Services Director of Sales, Western Region, U.S.A. We're also delighted to share that Ranjit Pradhan has been elevated from Head of Marketing and customer advocacy to Vice President of Customer Advocacy and Global Marketing. In this new role, Mr. Pradhan carries 30 years of health care experience, having held positions in product management, marketing, technology, and general management at Fortune 100 companies and global leaders including GE, Abbott, Elekta, Sysmex and Philips; in connection with our purchase of a 60% interest in three radiation therapy centers located in Rhode Island, we announced that Greg Mercurio has been appointed as our Senior Vice President of Radiation Oncology. Mr. Mercurio comes to this position with deep expertise in the radiation oncology field, among it 20 years spent on Certificate of Need attainment for developing and operating radiation therapy facilities. He has established a solid web of relationships with physicians, hospitals and OEMs to make high-technology medical equipment more accessible. For 15 years, Mr. Mercurio worked for a nationally renowned radiation therapy provider, where he devised strategy for obtaining Certificates of Need to launch five radiation therapies centers in Rhode Island through joint venture ship partnership with five community hospitals, treating more than 1,000 patients annually and bringing in $9 million to $10 million a year in revenue. He also has worked as a radiation business consultant for major health care systems around the country, freestanding radiation oncology providers, and manufacturers or radiation therapy products; so, as you can tell, we have a strong senior management team in place to generate further momentum as we keep carrying out our growth strategy. Let's now move to the results for the quarter. We're happy to share that AMS delivered a good first quarter, and we're very excited about what lies ahead this year. We've kept demonstrating progress in the market and advancements on several key fronts. One clear example is our sales organization, which is carrying good momentum, and the opportunities we're tracking are very robust. In fact, thanks to the Rhode Island acquisition we recently completed, our anticipated revenue backlog has grown by more than 100%, now exceeding $210 million. That reflects not just the strength of the team, whose reputation in our industry is well established, but also the broader financial solutions we now offer and tighter coordination with our strategic OEM partners. Taken together, these elements have substantially widened the range of opportunities we're evaluating. Those opportunities span multiple advanced radiation therapy equipment deployments across different settings, plus an extension of our business model into developing and operating proton beam and radiation oncology centers in the United States where we hold majority ownership. Our team remains dedicated to reinforcing the core business by collaborating with customers to boost how much their equipment is used. That disciplined approach produced four lease extensions signed with our 10 domestic Gamma Knife customers during the past 12 months. Additional ones are in the works. We see these extended agreements as evidence of both our partnership-driven business model and our financial adaptability. What stands out is how much higher this is compared with earlier years, which speaks to our commitment, resolve, and ability to execute. International performance has kept accelerating as well. During the first quarter, volumes rose after we finished upgrading equipment in Ecuador to a new state-of-the-art Gamma Knife ICON — the sole Gamma Knife in Ecuador for non-invasive radiosurgery. Our Gamma Knife in Peru, likewise the only one in that nation, also delivered outstanding results in the first quarter. Our third international center, located in Puebla, Mexico, is still expected to start treating patients within the next 60 days. This newly opened linear accelerator we're installing in Puebla, Mexico will feature VMAT, IGRT and radiosurgery capabilities, providing the most advanced radiation therapy offered in that Puebla, Mexico catchment area. We're also continuing to put money into the three distinctive business opportunities in Rhode Island that we discussed before. The earliest of these transactions was announced in the fourth quarter, covering the purchase of a 60% majority stake in three radiation therapy centers in Rhode Island. That deal closed last week. These represent our first direct patient services, or retail centers, within the United States. This new business, the first to emerge from our expanded team and fresh pipeline, plainly demonstrates the scale of our ambitions for the company. We opened the year with a strong quarter, posting total revenue of $5.2 million in the first quarter, up 5.9% from the same period a year earlier. Gross margin reached $2.1 million, an increase of 12.3%, which mirrors disciplined management of direct costs and favorable operating leverage. The gross margin percentage was 41%. We generated $0.02 per share in the quarter, a modest decline from $0.03 per share in last year's first quarter. Our balance sheet is still in solid shape. At the close of Q1, our cash and equivalents stood at more than $13 million, which works out to about $2 for each share. On March 31, 2024, we still owed $2.4 million against our $7 million credit facility, and that balance was repaid ahead of schedule during Q2 2024. We keep putting these funds to work prudently in pursuit of extra long-term revenue streams. Looking ahead over the next several months, we anticipate greater international expansion driven by added treatment capabilities in Ecuador, sustained high volumes from our Peru center, and the launch of our new facility in Puebla. The Rhode Island acquisition we recently completed brings three additional revenue streams into our company. Beyond those fresh business prospects, which are progressing through our pipeline via that complex and lengthy sales cycle. We look forward to revealing further specifics when the moment is right. Having said that, I'll hand things over to Bob to walk through the financials.

Bob Hiatt

executive
#3

Thank you, Ray, and good afternoon, everyone. First-quarter revenue climbed 5.9%, coming in at $5.2 million, compared with $4.9 million in the same quarter a year ago. As we noted earlier, we've restructured our business segments so that they better reflect where our revenue is generated. Leasing revenue — which we now refer to as the medical equipment leasing segment — totaled $4.3 million in the first quarter of 2024, against $4.2 million in last year's first quarter, amounting to a 0.6% increase. The direct patient services segment, also called retail, produced $963,000 in the quarter that ended March 31, 2024, versus $696,000 a year before, an increase of 38.4%. Equipment upgrades in Ecuador delivered added capacity as well as an improved patient experience and volume, while revenues in Peru rose on the strength of promoting the center throughout the country, and those factors combined to drive the gain. Our proton therapy system in Florida contributed $2.6 million of first-quarter revenue, an increase of 14.5%, largely because average reimbursement continued to rise even as traction fell. Proton therapy fractions reached 1,276 in the first quarter, down from 1,536 fractions in the first quarter of 2023 — a decline of 16.9% that we attribute to normal, cyclical fluctuation. Total Gamma Knife revenue dipped modestly, by 1.7%, to $2.6 million, since procedures dropped off from two expired contracts and since two sites experienced downtime while upgraded equipment was being installed, although strong volume at our other locations, particularly Peru and Ecuador, almost offset that. For context, Gamma Knife procedures totaled 273 in the first quarter, compared with 293 a year earlier in the same quarter. That said, excluding the two customer contracts that expired, Gamma Knife procedures for the first quarter of 2024 increased by 10, or 4%. Gross margin for the first quarter of 2023 increased — pardon me, for the first quarter of 2024 — increased 12.3% to $2.1 million, versus gross margin of $1.9 million in the first quarter of 2023. Selling and administrative costs for the first quarter of 2024 rose 22.1% to $1.9 million, compared with $1.5 million in the year-ago quarter. That figure includes roughly $377,000 we've invested in pursuing new business opportunities, as Ray discussed. Net interest expense was $237,000 in the 2024 period, versus $184,000 in the same period a year earlier. That rise reflects higher interest rates and more borrowings on the company's variable rate debt, partly offset by greater interest income from the company's strong cash balance. The operating loss for the first quarter of 2024 was $85,000, compared with operating income of $98,000 in the first quarter of 2023, reflecting higher selling and administrative expense tied to our recent Rhode Island activity. During 2024's opening quarter, we recorded an income tax benefit amounting to $44,000, whereas in the comparable period a year earlier we had income tax expenses of $68,000. Fully diluted weighted average common shares outstanding were $6,576 million and $6,472 million for the first quarter of 2024 and 2023 respectively. That change was largely driven by a movement in our deferred tax valuation allowance. For the first quarter of 2024, net income attributable to American Shared Hospital Services totaled $119,000, equating to $0.02 per diluted share, compared with net income of $188,000, or $0.03 per diluted share, in the first quarter of 2023. When it comes to fully diluted weighted average common shares outstanding, the figures were 6,576,000 for the first quarter of 2024 and 6,472,000 for the first quarter of 2023. Adjusted EBITDA, a non-GAAP financial measure, came in at $1.7 million for the first quarter of 2024, a decline from $1.9 million in the first quarter of 2023. Cash, cash equivalents and restricted cash amounted to $13.04 million at March 31, 2024, versus $13.81 million at December 31, 2023. At March 31, 2024, shareholders' equity, excluding noncontrolling interest in subsidiaries, was $22.84 million, or $3.61 per outstanding share, compared with $22.62 million, or $3.59 per outstanding share, at December 31, 2023. With that, the formal portion of our presentation is done. Thank you for being with us today. We look forward to sharing updates on our progress in the quarters ahead. Operator, we'd now like to turn the call back over to you and start taking questions.

Marla Marin

analyst
#4

So clearly, the results are quite strong. I'm curious about what happens when a device gets upgraded. And obviously, that's a topic you're discussing with customers. At the time of an upgrade, is there some downtime tied to it, even once the equipment has been set up at the site, because the medical staff who will operate the device need to be trained?

Ray Stachowiak

executive
#5

Yes, downtime does occur. Whenever a Gamma Knife is upgraded — and we've completed several of those lately — the typical period is roughly 60 days of downtime: taking out the old Gamma Knife, putting in the new one, and then working through the credentialing process and commissioning of the new Gamma Knife. So it comes to around 60 days, give or take — I'd say 15 to 30 days on that 60-day time line — of downtime.

Marla Marin

analyst
#6

All right, understood. Then here's my follow-up question. With the Rhode Island facilities now added, would it be reasonable to say that the equipment is already there, that the staff has already been operating it, and therefore you don't expect any downtime at all? Or is that not how we should look at it?

Ray Stachowiak

executive
#7

No — the right way to look at it is that downtime simply doesn't exist. On Tuesday, May 7, which was the seller's final day of ownership, they were treating patients, and on Wednesday, May 8, our first day of ownership, they are treating patients. That revenue is going to land on our books in the second quarter, starting with the patients treated last week, Wednesday, May 8, and they're on. That's one of the advantages of an acquisition like this one — you receive an instant lift in revenue and profitability from the deal. And I compare that with the agreement we signed in Puebla, Mexico, where we're installing the equipment and expect to treat our first patient within the next 60 days, yet we signed that agreement almost 2 years ago. Signing an agreement for a joint venture like the one in Puebla, Mexico does take some time, and revenue doesn't begin for a longer stretch depending on licensing and commissioning and the training that goes into preparing the facility itself.

Analyst

analyst
#8

Great quarter, everyone. I'd like to ask about those two fresh growth possibilities up in Rhode Island. Could you describe how long getting the Certificates of Need tends to take? While that's pending, can you also move ahead with securing land for both the new proton beam facility and the new radiation center? If you could take us through the timeline starting now, including build time, and explain how that shapes up, that would help.

Ray Stachowiak

executive
#9

Excellent question, and I appreciate you raising it. Let me clear something up, because at times I want to be certain everybody follows this: we've actually been chasing three possibilities in Rhode Island. The first is buying those three radiation therapy centers — please don't mix things up and think the three possibilities are the three radiation therapy centers we recently purchased. That's possibility number one in Rhode Island: three radiation therapy centers. Possibility number two involves launching a fourth radiation therapy center, one we'd essentially construct from scratch, and our preference isn't really to hold the real estate — most likely we'd rent it from a REIT — while we'd still own and run the radiation therapy center inside it. That building is aimed at Bristol, Rhode Island, located on the eastern side of the state, and I'd describe it as an underserved community. We anticipate a hearing on the needed CON in the very near future, and I'm confident it will be favorably received, I'll put it that way. Now, regarding possibility number three, and to add a note on the Bristol building: getting it constructed and the equipment installed will require a fair amount of time. My estimate is that revenue there, along with the first patient receiving treatment, sits roughly 12-plus months away — so let me set expectations accordingly for that possibility. Possibility number three, the last one, comes with an even lengthier timeline. We've filed for a CON to run a proton beam radiation therapy center that we'd own and operate in Rhode Island. We have a chosen site for it that we aren't ready to reveal yet. That CON's hearing hasn't been scheduled so far, meaning we're waiting for the Rhode Island Department of Health to set a date for it regarding the proton beam CON. The proton beam's timeline stretches out even more. My estimate: after a CON is secured, the first patient might not be treated for two, occasionally as many as three years, even assuming we move quite aggressively on land acquisition and construction design. Building the vault is an extremely complicated project. So that timeline extends considerably further. Still, patience here is absolutely worthwhile. Our proton beam partnership down in Orlando, Florida, has gone extremely well for us; and anything worthwhile doesn't happen overnight.

Analyst

analyst
#10

All right. That's useful context. Then, to follow up on the new site in Puebla, Mexico — from what I recall in the press release, you folks indicated the first patient would receive treatment within the next 60 days. Could you clarify whether that represents a longer timeframe than what had originally been anticipated for the startup? And additionally, when it comes to ramping up a facility like that, could you provide some sense of how much time is required before reaching more or less full capacity over time?

Ray Stachowiak

executive
#11

The timeline for getting Puebla up and running is something we're disappointed about. And I have to say that largely, it involved matters beyond our control. The regulatory situation, the licensing, the credentialing, the construction — as much as our team has attempted to speed up the launch of services at that center, it simply hasn't been completed. And honestly, that leaves me somewhat disappointed. I have — when you mention full capacity, I'd like to grasp what you mean by that full capacity idea, Aaron?

Analyst

analyst
#12

So, let's say the machine operates at 100% capacity with no breaks — at what point does the first patient get treated? What does that timeline look like, and is it possibly just at 10% of the machine's capacity initially, increasing over time? How should we think about that progression?

Ray Stachowiak

executive
#13

The ramp-up should be gradual in my view, though it will keep building steadily. In most cases, equipment never hits maximum capacity, and reaching that maximum isn't required for profitability. Naturally, we'd like to run at maximum capacity since our cost structure under those conditions is largely fixed. Greater utilization improves the bottom line — nearly everything flows straight down — so we're always pushing to raise that capacity.

Ray Stachowiak

executive
#14

Appreciate that, Jamie, and thanks as well to each of you for being here today. Our outlook has us genuinely enthusiastic, and we see AMS sitting right at a major turning point — particularly given that our expected revenue backlog has grown to almost twice what it was compared with a year earlier. We're eager to share news about how things keep moving forward. Should anything come up before then, feel free to reach out to us straight away. We're grateful that your interest in American Shared Hospital Services remains strong. Enjoy the rest of your day.

Operator

operator
#15

That brings us to the end of today's conference call and presentation, everyone. We appreciate your participation. You're free to hang up at this time.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete American Shared Hospital Services transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

For developers and AI pipelines

Programmatic access to American Shared Hospital Services earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in American Shared Hospital Services or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.